Invezz
07 Jul 2026, 13:38 UTC · 19w ago
Crinetics shares surge after Vertex agrees to $10B cash buyout
Impact · against what's priced in
Vertex's acquisition of Crinetics creates an immediate price floor for CRNX at $85 per share. For VRTX, the deal provides a strategic expansion into endocrinology with significant projected peak sales, though the impact is more gradual than the immediate catalyst for CRNX.
- CRNX+1.00
No priced-in read yet
- In context
The all-cash buyout at $85 per share represents a 100%+ premium, creating a concrete target price and a significant immediate floor for the stock.
Read from the article alone

Top 1 mover · tap to explore




